EPAD Scotland

Title: European Prevention of Alzheimer's Disease Scotland Longitudinal Cohort Study

Short title: EPAD Scotland

Sponsor:  ACCORD

Chief Investigator: Prof Craig Ritchie, University of Edinburgh

Edinburgh PI: Prof Craig Ritchie, University of Edinburgh

Ethics ref: 21/NI/0100

Funder: Alzheimer’s Disease Drug Foundation (ADDF), and Scottish Neurological Research Fund (SNRF)

Dates (estimated): April 2022 - Ongoing (subject to funding)

Synopsis: The European Prevention of Alzheimer’s Disease (EPAD) longitudinal cohort study (LCS) ended in 2020. EPAD was a large European wide collaboration aimed at understanding dementia and forming clinical trials of new medicines to fight against Alzheimer’s disease. EPAD generated a rich pool of cognitive, neuroimaging, clinical and biomarker data, which is to be used to identify early risk factors for Alzheimer’s disease. Now, follow-on studies to EPAD are being set up locally within each host country in order to continue collecting longitudinal data from previous EPAD participants and from new participants. This new data will complement the existing data by building longitudinal models of change in early Alzheimer’s disease. 

Aims:  To find the earliest cognitive and biological markers of Alzheimer’s disease

Recruiting: Yes. People without dementia who were previously enrolled on EPAD LCS are eligible to take part. People previously enrolled on the CHARIOT PRO study are also invited to take part. EPAD Scotland would additionally like to invite anyone aged over 50 who does not have a university degree to prticipate.  To find out more or register your interest please contact us or call 0131 651 7657. 

Links and Publications: EPAD website. EPAD Scotland featured on the EPAD blog.

The video below was featured on the EPAD LCS Youtube channel and describes Amyloid and the risk for Alzheimer's Disease, as well as how study participants may be invited to take part in clincial trials on Amyloid in the future.